Myasthenia Gravis: Clinical Manifestations, Epidemiology, Pathophysiology, Diagnosis, Current and Future Therapies
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Clinical Neurology".
Deadline for manuscript submissions: closed (31 May 2021) | Viewed by 137965
Special Issue Editor
Special Issue Information
Dear Colleagues,
Myasthenia gravis (MG) is the most common disease of neuromuscular transmission. It is caused by production of antibodies against receptors in the neuromuscular junction. The incidence rate of MG is estimated to be 0.3–2.8 per 100,000, with an estimated prevalence rate of 5.35–35 per 100,000. While MG is often a mild disease localized to the extraocular muscles, it may result in weakness affecting the bulbar, limb, or respiratory muscles. MG is a treatable condition, but patients very often suffer from significant morbidity, though this rarely results in mortality. Treatment of MG consists of symptomatic management and immunomodulatory treatment. MG is currently the focus of extensive research, aimed both at unraveling the pathophysiological mechanisms and also the discovery of new therapeutic approaches that are more effective and have less adverse effects than the currently available treatments. In this issue, the authors will discuss the epidemiology, clinical manifestations, differential diagnosis, pathophysiology, diagnostic approach, current pharmacological treatment, and oncoming therapies, i.e., drugs in the pipeline.
Dr. Kourosh Rezania
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Myasthenia Gravis
- AChR
- MuSK
- Immunotherapy
- Prednisone
- Eculizumab
- Pyridostigmine
- Tacrolimus
- Rituximab
- Complement
- Neonatal FC receptor
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.